Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:1 Issue:5 Number:83 ISSN#:2563-5476
Author Verified
RCT
ACE Report #335
Ace Report Cover Arthroplasty

Rivaroxaban is an adequate treatment for thromboprophylaxis after total knee arthroplasty


Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial

Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4

Contributing Authors: AG Turpie MR Lassen BL Davidson KA Bauer M Gent LM Kwong FD Cushner PA Lotke SD Berkowitz TJ Bandel A Benson F Misselwitz WD Fisher RECORD4 Investigators

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

3148 patients who underwent total knee arthroplasty (TKA) were randomized to thromboprophylaxis using either orally administer rivaroxaban or subcutaneous injection of enoxaparin. This study assessed the efficacy of thromboprophylaxis treatment with rivaroxaban and assessed its non-inferiority to enoxaparin. The results of this study indicated that rivaroxaban was superior in comparison to enoxapa...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.